Best practices as recommended by WHO and United States Pharmacopoeia are being implemented for performing tests on therapeutic goods.
Recent Updates
- DRAP Releases 2nd Edition of Guidelines for Good Clinical Practice (GCP) Inspections March 18, 2024
- Recall Alert: Drug Product; Barpon 100mg/5mL Suspension (Batch # 202) by M/s. JASM Pharmaceutical, KPK March 14, 2024
- Rapid Alert: Substandard Propylene Glycol (Batch # G01821UG) claimed to be manufactured by SK Picoglobal Korea. March 8, 2024
- Switching Over to Pakistan Single Window (PSW) for Drug Import License and Import Release of Donations Medicines March 7, 2024
- Rapid Alert: Contaminated Propylene Glycol Identified and Confiscated March 7, 2024
- Guidelines on Risk Based Sampling and Testing of Drugs; Comments invited on draft Document March 1, 2024
- Minutes of 295th Meeting of Central Licensing Board held on 11th January 2024 March 1, 2024
- Recall Alert: Drug Product; DXL 60mg Capsule (Batch # 23136) by M/s. Titlis Pharma Lahore February 28, 2024
- Recall Alert: Drug Product; Mencobal 500mcg Injection (Batch # 082) by M/s. Treat Pharmaceutical Industry (Pvt.) Ltd.,Bannu. February 28, 2024
- Recall Alert: Drug Product; SN ZOR 200mg/5mL Suspension (Batch # 342) by M/s. S.N.B Pharma (Pvt) Ltd. Peshwar February 27, 2024
Leadership
E-Services
With the effective use of Information Technology, we have implemented a number of online services and continually working for more. Click Here to Register an account for following online services. Online Challan & Fee Submission fee.dra.gov.pk Commercial Import & Export
Guidelines
Regulatory compliance is essential and indispensable in order to assure the safety, quality and efficacy of therapeutic goods. Guidance documents published by the Authority are meant to explain the current interpretation or policy for better understanding of the industry and
Quality Control Labs
For ensuring quality therapeutic goods, a network of quality control laboratories has been established. DRAP approved products and suspect therapeutic goods are tested for their quality in accordance with best international practices. To keep the citizens safe from substandard and
Therapeutic Products Recalls
The Recalled Product Index provides access to consumers, healthcare professionals, industry, hospitals and sale outlets related to the information of recalled action taken for defective therapeutic goods. The following section provides an index of recalled actions in which a public
Health Professional Alerts
DRAP’s issues safety updates and alerts related to the therapeutic goods in order to ensure that healthcare professionals and other stakeholders have timely access to the relevant information on safety, quality and efficacy issues or benefit/risk evaluations of the drugs,
Open Consultations
Public consultation enables organizations to consider views and ideas from the citizens and relevant stakeholders during the development of new regulatory mechanisms, either through the enactment of new rules and policies or changes to existing ones or by the development
Implementation of eApp
We are delighted to announce that DRAP has enabled eApp for Drug Licensing & Registration application submissions.
Do you know?
DRAP ensures that every drug, medical device or cosmetic, alternative medicine and health product must have a certain standard of quality and is safe and effective for your use. See in links below how it is done and what to do in case you find a suspect therapeutic good.